Dementia Risk Registry for Young and Middle-aged CSVD Patients in the Next 10 Years

Launched by ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL · Dec 8, 2023

Keywords

ClinConnect Summary

The DREAM-10 trial is studying how cerebral small vessel disease (CSVD) may affect the risk of dementia in younger and middle-aged people, specifically those aged 30 to 60. CSVD is a condition that can cause changes in the brain, often seen in imaging tests like MRI, but it is most common in older adults. This study aims to gather information from participants who have specific imaging markers related to CSVD but do not have dementia. By following these participants over the next ten years, researchers hope to understand how CSVD might lead to cognitive decline and identify factors that could predict this risk.

To participate in this trial, individuals must be between 30 and 60 years old and have certain CSVD-related findings on their brain scans. They also need to be able to provide consent to join the study. Participants will undergo regular check-ups, including brain imaging and cognitive assessments, to monitor their health over time. This trial is important because it could help identify younger individuals at risk for dementia and lead to better ways to manage their health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with any of the CSVD-related MRI imaging markers, including recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and superficial cortical siderosis.
• • 2. Patients aged from 30 to 60 years.
• • 3. Sign informed consent.
• Exclusion Criteria:
• • 1. Unable to cooperate with inspectors.
• • 2. Known dementia.
• • 3. Other cognitive diseases (such as Alzheimer's disease, Parkinson's disease, or thyroid disease).
• • 4. Serious systemic illness, such as heart, liver, kidney disease or major mental illness.
• • 5. Contraindications for imaging examination.
• Exit Criteria:
• • 1. Not meet the inclusion criteria.
• • 2. For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator.
• • 3. Any adverse or serious adverse events during the study period judged by investigator.